Zhitong Finance APP News, Hengrui Pharmaceutical (600276omahapokervideos.SH) issued an announcement that the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd.omahapokervideosSHR-A1921 for injection is planned to be included in the publicity list of breakthrough treatment varieties by the Center for Drug Evaluation of the State Food and Drug Administration, with a publicity period of 7 days. Proposed indication (or functional indications) of this drug: It is used to treat platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer.
